- Home
- CHW vs BCYC Comparison
CHW vs BCYC Comparison
Compare CHW & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHW | BCYC |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.4M | 476.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CHW | BCYC |
|---|---|---|
| Price | $7.97 | $7.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 195.2K | ★ 240.6K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 9.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.07 | $6.03 |
| 52 Week High | $6.54 | $13.63 |
Technical Indicators
Market Signals| Indicator | CHW | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 71.39 | 54.96 |
| Support Level | $7.65 | $6.85 |
| Resistance Level | $7.90 | $7.34 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 95.38 | 72.18 |
Price Performance
Historical ComparisonAbout CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.